Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab.
JAMA Dermatol
; 160(6): 678-681, 2024 Jun 01.
Article
in En
| MEDLINE
| ID: mdl-38717768
This post hoc analysis of PIONEER I and II randomized clinical trials assesses whether receiving adalimumab is associated with decreased hematologic abnormalities and increased clinical improvement in patients with hidradenitis suppurativa.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hidradenitis Suppurativa
/
Adalimumab
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
JAMA Dermatol
Year:
2024
Document type:
Article